Guillermina Remaggi

[Ankit kansagra @kansagraMD]

Phase 3 readout from MonumenTAL-6 — and the effect size here is hard to ignore.

MonumenTAL-6 | Phase 3 | relapsed/refractory myeloma, 1–4 prior lines (anti-CD38– and len–exposed) - patient population with true unmet need in clinic.

Two off-the-shelf bispecifics, together, moved earlier in the disease course:
TECVAYLI (teclistamab, anti-BCMA) + TALVEY (talquetamab, anti-GPRC5D)

PFS HR 0.11 → 89% reduction in risk of progression or death https://t.co/qtaoBbwdyn

OS HR 0.38 → 62% reduction in risk of death

vs investigator's choice (EPd / PVd)

The TALVEY + pomalidomide arm also beat standard of care (PFS HR 0.27).

An HR of 0.11 in a randomized Phase 3 isn't a number we see often. The real story is the dual BCMA/GPRC5D doublet truly emerging as SOC in early relapse

Grateful to the entire MonumenTAL-6 team. This was a true group effort, and I'm proud to have an opportunity to help advance this amazing therapy for our patients.

Check out our ASH 2024 Abstract of Trial in progress for study design - https://t.co/w0Jzzbl7nb

@myelomaMD @AjayNookaMD @bhemato @HiraSMian @mpianko @paurotero @JNJNews @gjmccaughan @oncodaily @OncBrothers @KolPulseAI @MM_Hub

#Myeloma #Bispecifics #mmsm

[Benlazar S M A @smbenlazar]

How I treat plasma cell leukemia https://t.co/yZg9E5vriF #mmsm

[Mohamad Mohty @Mohty_EBMT]

@VincentRK @COMyCongress @myelomaMD

[Vincent Rajkumar @VincentRK]

Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI

Implications are HUGE. This is a drug we spends billions on each year:

-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD

National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG

https://t.co/k8nGWeSA03

[Nico Gagelmann @NicoGagelmann]

Very excited to see the first episode out!

PTCy - for ALL donors?

Post-transplant cyclophosphamide revolutionized the field, offering new hope to patients worldwide.

How did all this start, where are we now?

Thanks to whole team of @MythsFactsPod

https://t.co/UwsTZLwHbv

[Muzaffar Qazilbash @Transplant_Doc]

Impact of doublet post-ASCT maintenance in MM: A propensity score matching analysis. N=410 (doublet: 80, monotherapy: 330); superior EFS and OS with a doublet #mmsm #bmtsm @AJPortuguese https://t.co/NotB9gqBtY

[Vincent Rajkumar @VincentRK]

I’ll update my relapsed myeloma algorithm on @OpenMedInsights @OpenMedicineHQ soon. https://t.co/EDYrUNC9BB @scserendipity1

[Carmelo Gurnari @CarmeloGurnari]

I am so thrilled to share our latest @TheEBMT guidelines on donor-derived hematological neoplasia: how to tackle these cases?? Read here👇 (link below) or listen to the @TheLancetHaem podcast! (Link below too)

[Vincent Rajkumar @VincentRK]

Based on the latest data at #ASCO26 awe can consider bispecifics especially teclistamab (has the most data) alone or in combination with daratumumab in first relapse of myeloma.

Here is our latest https://t.co/x9KJzoJyXJ approach to first relapse.

[Guillermina Remaggi @guilleremaggi]

@gelamm_latam 👏🏻👏🏻👏🏻💪🏻

[Meral Beksac @mbeksac56]

#COMY26 RESPONSE TO MYELOMA from the Blade criteria to the emerging 2026 IMS/IMWG criteria by @myelomaMD

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

CELMoDs - that much closer to clinic 👏

SUCCESSOR-2 press release: Mezi-Kd beat Kd in registrational Ph3 trial. Data no doubt coming soon!

I love KPd and will love this 100x more as pre-CAR holding/bridging or post-CAR/bsAb failure. T cells ❤️ mezi!

https://t.co/umLNroSwxP

[Vincent Rajkumar @VincentRK]

This changes how we approach first relapse.

In Dara sensitive patients: Tec-Dara or Cilta-cel are the top two choices.

If Dara refractory: Bispecifics alone or Cilta-cel are the main options.

CART and Bispecifics both need close monitoring and specialized care and certain requirements. So for some patients, we may still use triplets.

[Vincent Rajkumar @VincentRK]

Just in: Good news for the myeloma field.

FDA approves teclistamab plus daratumumab (Tec-Dara) combination for myeloma for patients who have had at least one prior line of therapy.
Note: Always use Tec-Dara with monthly IVIG. It’s not optional.

That was fast! And this is unprecedented curve is why.

[Guillermina Remaggi @guilleremaggi]

@CarmeloGurnari @VJHemOnc @MDSFoundation @aamdsif @ClevelandClinic @TorVergataTV @unitorvergata 👏🏻👏🏻👏🏻

[Vincent Rajkumar @VincentRK]

Here is the full story and how this trial dramatically affects practice. #ASH25

Any other slides you need from presentation, request in thread.
@mvmateos @End_myeloma

[Vincent Rajkumar @VincentRK]

Unprecedented. #ASH25

Tec-Dara in relapsed myeloma.
@mvmateos

[Vincent Rajkumar @VincentRK]

Just out in @NEJM
Effective therapy of extra medullary relapsed myeloma with teclistamab plus talquetamab (Tec-Tal). RedirecTT-1 #ASH25
@myelomaMD @szusmani @mvmateos

80% response rate.
60% PFS at 12 months.
https://t.co/fqAPu4pMUc

[Vincent Rajkumar @VincentRK]

630am
250+ myeloma docs
Standing room only, to the rafters. #ASH25

https://t.co/VFCSHjIiJ6
#IMWG #IMFASH25

[Guillermina Remaggi @guilleremaggi]

@elonmusknews30 A